M. Mitton-Fry

发表

Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide

Mark J. Mitton-Fry, R. Wallis, D. Paige, 2012, PloS one.

New analyses of MIC90 data to aid antibacterial drug discovery

Max Kuhn, Matthew Frank Brown, Rishi R. Gupta, 2011 .

Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.

V. Shanmugasundaram, M. Huband, T. Harris, 2012, Bioorganic & medicinal chemistry letters.

Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.

T. Gootz, M. Huband, S. J. Brickner, 2011, ACS medicinal chemistry letters.

Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy

A. Gonzales, J. Bowman, G. Fici, 2014, Journal of veterinary pharmacology and therapeutics.

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.

Mark J. Mitton-Fry, J. D. Clark, M. Hegen, 2018, Journal of medicinal chemistry.

Serendipitous Discovery of a Competitive Inhibitor of FraB, a Salmonella Deglycase and Drug Target

S. Lindert, B. Ahmer, V. Wysocki, 2022, Pathogens.

Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis

R. Wallis, Vikas Kumar, D. Paige, 2010, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.

G. Friedland, R. Wallis, Vikas Kumar, 2010, The Journal of infectious diseases.

Process Development for the Synthesis of Monocyclic β-Lactam Core 17

Jeremy T Starr, Matthew F Brown, M. Lall, 2018 .

Aryl Methyl Ketones: Versatile Synthons in the Synthesis of Heterocyclic Compounds

M. Mitton-Fry, Shabber Mohammed, Jason West, 2022, SynOpen.

Pyridone-conjugated monobactam antibiotics with gram-negative activity.

V. Shanmugasundaram, M. Huband, T. Harris, 2013, Journal of medicinal chemistry.

Total synthesis of dermostatin A.

C. Arpin, Aaron J. Cullen, T. Sammakia, 2011, The Journal of organic chemistry.

The total synthesis of the oxopolyene macrolide RK-397.

Aaron J. Cullen, T. Sammakia, M. Mitton-Fry, 2007, Angewandte Chemie.

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

M. Huband, A. Marfat, J. Driscoll, 2013, Bioorganic & medicinal chemistry letters.

Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors Exhibit Bactericidal Activity against Planktonic and Biofilm Staphylococcus aureus In Vitro

Mark J. Mitton-Fry, D. Wozniak, Anna Chen, 2022, Microbiology spectrum.

Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.

V. Shanmugasundaram, K. Leach, M. Huband, 2012, Journal of medicinal chemistry.

Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA.

Mark J. Mitton-Fry, S. Lindert, C. McElroy, 2021, Journal of medicinal chemistry.

Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive Staphylococcus aureus.

S. Lindert, D. Wozniak, Justin T. Seffernick, 2020, ACS medicinal chemistry letters.

Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor.

M. Munchhof, T. Harris, J. Driscoll, 2010, Bioorganic & medicinal chemistry letters.

The identification of orally bioavailable thrombopoietin agonists.

A. Marfat, M. Munchhof, T. Harris, 2009, Bioorganic & medicinal chemistry letters.

Novel bacterial topoisomerase inhibitors derived from isomannide.

Mark J. Mitton-Fry, J. Gallucci, A. Okumu, 2020, European journal of medicinal chemistry.

Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.

Mark J. Mitton-Fry, V. Shanmugasundaram, Ye Che, 2012, Bioorganic & medicinal chemistry letters.

Novel Bacterial Type II Topoisomerase Inhibitors

Mark J. Mitton-Fry, M. Mitton-Fry, 2017 .

1,3-Dioxane-Linked Bacterial Topoisomerase Inhibitors with Enhanced Antibacterial Activity and Reduced hERG Inhibition.

S. Lindert, L. Koeth, A. Okumu, 2019, ACS infectious diseases.

1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.

Mark J. Mitton-Fry, N. Osheroff, M. Hazbón, 2022, ACS medicinal chemistry letters.

Synthesis and anti-staphylococcal activity of novel bacterial topoisomerase inhibitors with a 5-amino-1,3-dioxane linker moiety.

Mark J. Mitton-Fry, A. Okumu, D. Wozniak, 2018, Bioorganic & medicinal chemistry letters.

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mark J. Mitton-Fry, M. Huband, A. Marfat, 2017, Bioorganic & medicinal chemistry letters.

Actions of a Novel Bacterial Topoisomerase Inhibitor against Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enhancement of Double-Stranded DNA Breaks

Mark J. Mitton-Fry, N. Osheroff, Jessica A Collins, 2023, International journal of molecular sciences.

Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive Staphylococcus aureus.

Mark J. Mitton-Fry, S. Lindert, D. Wozniak, 2020, ACS medicinal chemistry letters.

Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis

R. Wallis, Vikas Kumar, D. Paige, 2010, Antimicrobial Agents and Chemotherapy.

Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs

Mark J. Mitton-Fry, J. Yalowich, M. Mitton-Fry, 2023, Antimicrobial agents and chemotherapy.